News by topic

Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Hepatitis and HIV news

Show

From To
Hepatitis B
Arrowhead data demonstrates RNAi candidate ARC-520 silences hepatitis B virus

Single injection induces multi-log repression of viral RNA, proteins, and viral DNA; Long duration of effect lasting over 30 days; Regulatory submissions planned for Q2 2013.

Published
27 February 2013
From
Arrowhead Research Corp press release
Hepatitis B
FDA rejects Dynavax's adult hepatitis B vaccine on safety concerns

U.S. health regulators denied approval for Dynavax Technologies Inc's adult hepatitis B vaccine pending additional data to evaluate its safety, potentially delaying the U.S. market entry of the company's first promising product.

Published
26 February 2013
From
Reuters
Hepatitis C treatment
Hepatitis C Model Delivers Great Care Anywhere

Optimal HCV treatment for patients in a comprehensive health system requires an efficient and effective process. Ideally, the established structure would support rural as well as urban settings and allow for sharing of information, education of providers, and metrics to monitor treatments. Such a process was established successfully within the Department of VA.

Published
25 February 2013
From
Infectious Disease Special Edition
Access to medicines and treatment
UNITAID can address HCV/HIV co-infection

In the first days of March, the governing body of UNITAID, the organisation financed mainly through a levy on air tickets, will decide on a new 4-year strategy. We believe UNITAID's new strategy should also include tackling a prevalent and serious, but curable, HIV co-morbidity: hepatitis C virus (HCV) infection.

Published
23 February 2013
From
The Lancet
New and experimental hepatitis C treatment
Regulators Await Gilead's Hep C Candidate

Gilead Sciences’ (GILD) sofosbuvir has passed all its preliminary examinations, and now is looking like a good bet for regulatory submissions in the coming months.

Published
22 February 2013
From
Seeking Alpha
EASL publishes first comprehensive literature review on the burden of liver disease in Europe

Key findings in the report suggest that alcohol consumption, viral hepatitis B and C and metabolic syndromes related to overweight and obesity are the leading causes of cirrhosis and primary liver cancer in Europe.

Published
22 February 2013
From
Eurekalert Inf Dis
New and experimental hepatitis C treatment
Study may help design better DAA drug cocktails to treat HCV

The new study documents HCV kinetic modeling during treatment both in patients and in cell culture that provides insight into the modes of action of daclatasvir. In addition, the study suggests a more accurate estimate of HCV clearance from circulation.

Published
20 February 2013
From
News Medical
Hepatitis C transmission and prevention
Republic of Georgia plagued by hepatitis C

Official statistics place the number of those infected with the illness at 200,000, which is approximately 6.7 percent of Georgia’s population.

Published
20 February 2013
From
Vaccine News Daily
Hepatitis C transmission and prevention
Scotland: Project launched to tackle spread of Hepatitis C

It is hoped that by giving early treatment to small numbers of people who inject drugs and are infected with hepatitis C, it will prevent the need to treat larger numbers later, reducing the risk of addicts suffering from liver cirrhosis and cancer which can develop over time if hepatitis C remains untreated.

Published
20 February 2013
From
The Scotsman
New and experimental hepatitis C treatment
Gilead's Sofosbuvir for Hepatitis C Meets Primary Endpoint in Fourth Pivotal Phase 3 Study

Initial Regulatory Filings Planned for Q2 2013. Gilead Sciences (Nasdaq:GILD) today announced topline results from the Phase 3 FUSION study evaluating 12- and 16-week courses of therapy with the once-daily nucleotide sofosbuvir plus ribavirin (RBV) in treatment-experienced patients with genotype 2 or 3 chronic hepatitis C virus (HCV) infection who failed prior treatment.

Published
19 February 2013
From
Gilead press release
← Prev1...23456...94Next →

Filter by country